Automate Your Wheel Strategy on VTRS
With Tiblio's Option Bot, you can configure your own wheel strategy including VTRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTRS
- Rev/Share 12.1281
- Book/Share 13.0668
- PB 0.7783
- Debt/Equity 1.0687
- CurrentRatio 1.3513
- ROIC -0.0782
- MktCap 11713500900.0
- FreeCF/Share 1.4143
- PFCF 7.1116
- PE -3.2086
- Debt/Assets 0.4289
- DivYield 0.0472
- ROE -0.2269
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VTRS | Truist | -- | Buy | -- | $15 | Oct. 15, 2025 |
| Initiation | VTRS | Goldman | -- | Neutral | -- | $10 | June 6, 2025 |
News
Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.
Read More
Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. ( VTRS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good …
Read More
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
Read More
Viatris (VTRS) Reports Q3 Earnings: What Key Metrics Have to Say
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates
Published: November 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Viatris (VTRS) came out with quarterly earnings of $0.67 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.75 per share a year ago.
Read More
Countdown to Viatris (VTRS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Viatris (VTRS) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Is Viatris (VTRS) Stock Undervalued Right Now?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Teva Vs. Viatris: Who Will Dominate In President Trump's America?
Published: October 17, 2025 by: Seeking Alpha
Sentiment: Neutral
Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA-approved drugs and product candidates relative to the rival. By reading this article, you will learn which stock, Viatris or Teva, is more attractive in the long term.
Read More
Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
VTRS acquires Aculys Pharma to boost its CNS portfolio in Japan, gaining rights to pitolisant and Spydia for narcolepsy and seizure management, respectively.
Read More
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fifth Year in a Row
Published: October 08, 2025 by: PRNewsWire
Sentiment: Neutral
PITTSBURGH , Oct. 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This is the fifth year in a row that Viatris has received this recognition, which is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider.
Read More
Viatris: Indore Plant Could Boost 2026 Numbers
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Viatris continues to struggle with declining sales across all regions, with Q2-2025 net sales down 7% year over year. VTRS's Indore plant issues have significantly impacted results, but a full recovery in 2026 could lead to earnings beats versus consensus estimates. Despite capital returns, persistent sales declines and lack of progress in debt reduction raise concerns about VTRS's long-term investment viability.
Read More
Insider Watch: 3 CEOs Buying the Dip
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture.
Read More
Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer
Published: August 19, 2025 by: PRNewsWire
Sentiment: Neutral
PITTSBURGH , Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions.
Read More
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity PITTSBURGH , Aug. 11, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the U.S. Food and Drug Administration (FDA) has approved Iron Sucrose Injection, USP, an intravenous iron replacement product used to treat iron deficiency anemia (IDA) in adult and pediatric patients (2 years of age and older) with chronic kidney disease (CKD). IDA is a common complication of CKD and is associated …
Read More
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.
Read More
Viatris Inc. (VTRS) Q2 2025 Earnings Call Transcript
Published: August 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. (NASDAQ:VTRS ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Theodora Mistras - Chief Financial Officer William Szablewski - Former Head of Capital Markets Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Bhavin Patel - Bank of America, Research Division David A.
Read More
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Viatris (VTRS) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Negative
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Read More
Viatris Announces Five Data Presentations on Novel Fast-Acting Meloxicam (MR-107A-02) at PAINWeek 2025 Conference
Published: August 01, 2025 by: PRNewsWire
Sentiment: Neutral
Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokinetics data PITTSBURGH , Aug. 1, 2025 /PRNewswire/ -- Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference in Las Vegas from September 2-5, 2025. The presentations will include positive results from two previously announced pivotal studies in herniorrhaphy (NCT06215859) and bunionectomy (NCT06215820) surgery models.
Read More
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Negative
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
Read More
Kuehn Law Encourages Investors of Viatris Inc. to Contact Law Firm
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viatris Inc. (NASDAQ: VTRS) breached their fiduciary duties to shareholders.
Read More
Viatris Inc. (VTRS) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 10:40 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Scott Andrew Smith - CEO & Director Conference Call Participants Unidentified Analyst Great.
Read More
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.
Read More
Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference Transcript
Published: June 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Viatris Inc. (NASDAQ:VTRS ) Jefferies Global Healthcare Conference June 5, 2025 8:10 AM ET Company Participants Corinne M. Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Yuchen Ding Good morning, and welcome to the day 2 of the Jefferies Healthcare Conference.
Read More
VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Class Action Filed Against Viatris Inc. (VTRS) Over Securities Violations - Contact Levi & Korsinsky Today
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151471&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
Read More
VTRS DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important June 3 Deadline in Securities Class Action - VTRS
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / WHY: New York, N.Y., June 3, 2025.
Read More
Class Action Lawsuit Filed: Viatris Inc. (VTRS) - Join by June 3, 2025 - Contact Levi & Korsinsky
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151460&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Viatris Inc. (VTRS)
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=151437&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq.
Read More
About Viatris Inc. (VTRS)
- IPO Date 1980-03-17
- Website https://www.viatris.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Scott Andrew Smith
- Employees 32000